Coupland R W, Pontifex A H, Salinas F A
Cancer. 1985 May 1;55(9):1902-6. doi: 10.1002/1097-0142(19850501)55:9<1902::aid-cncr2820550912>3.0.co;2-0.
Eighteen patients with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) have been analyzed by reviewing all available biopsy, laboratory, and clinical data. Because of features suggesting the presence of circulating immune complexes (CIC), CIC serial sample determinations were performed throughout their disease in available patients. Age, sex, and clinical and laboratory characteristics were consistent with previously reported series. Six of 18 (33%) patients having a drug exposure associated with onset or exacerbation of symptoms demonstrated a significantly decreased survival (P less than 0.02). Achievement of complete remission was a significant indicator of longevity (P less than 0.001). Only one patient (6%) developed diffuse histiocytic lymphoma. Elevated CIC were detected in the four patients tested. In two patients fluctuating CIC levels could clearly be correlated to clinical remission or exacerbation. Despite the small number of patients tested, it was concluded tha CIC may provide useful information for therapy selection, prediction of relapse, and further insight into pathogenetic mechanisms in AILD.
通过回顾所有可用的活检、实验室及临床数据，对18例血管免疫母细胞性淋巴结病伴蛋白异常血症（AILD）患者进行了分析。鉴于存在提示循环免疫复合物（CIC）的特征，对有条件的患者在其整个病程中进行了CIC系列样本测定。年龄、性别以及临床和实验室特征与先前报道的系列一致。18例患者中有6例（33%）有与症状发作或加重相关的药物暴露史，其生存期显著缩短（P<0.02）。完全缓解是生存期的一个重要指标（P<0.001）。仅1例患者（6%）发生弥漫性组织细胞淋巴瘤。在检测的4例患者中发现CIC升高。在2例患者中，CIC水平波动与临床缓解或加重明显相关。尽管检测的患者数量较少，但得出结论认为，CIC可为AILD的治疗选择、复发预测以及对发病机制的进一步了解提供有用信息。
